Influenza B viruses exhibit lower within-host diversity than influenza A viruses in human hosts

Running Title: IBV diversity in human hosts

Andrew L. Valesano^{1,2}, William J. Fitzsimmons³, John T. McCrone⁴, Joshua G. Petrie⁵, Arnold S. Monto⁵, Emily T. Martin⁵, Adam S. Luring^{3,6} #

¹Program in Cellular and Molecular Biology, University of Michigan, Ann Arbor, MI; ²Medical Scientist Training Program, University of Michigan, Ann Arbor, MI; ³Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, MI; ⁴Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, United Kingdom; ⁵Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI; ⁶Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI

Corresponding author

Adam S. Luring

1150 W. Medical Center Dr.

MSRB1 Room 5510B

Ann Arbor, MI 48109-5680

(734) 764-7731

aluring@med.umich.edu

Abstract Word Count: 209

Main Text Word Count:

Key Words – influenza B virus, bottleneck, transmission, diversity, evolution

Abstract

Influenza B virus undergoes seasonal antigenic drift more slowly than influenza A, but the reasons for this difference are unclear. While the evolutionary dynamics of influenza viruses play out globally, they are fundamentally driven by mutation, reassortment, drift, and selection within individual hosts. These processes have recently been described for influenza A virus, but little is known about the evolutionary dynamics of influenza B virus (IBV) at the level of individual infections and transmission events. Here we define the within-host evolutionary dynamics of influenza B virus by sequencing virus populations from naturally-infected individuals enrolled in a prospective, community-based cohort over 8176 person-seasons of observation. Through analysis of high depth-of-coverage sequencing data from samples from 91 individuals with influenza B, we find that influenza B virus accumulates lower genetic diversity than previously observed for influenza A virus during acute infections. Consistent with studies of influenza A viruses, the within-host evolution of influenza B viruses is characterized by purifying selection and the general absence of widespread positive selection of within-host variants. Analysis of shared genetic diversity across 15 sequence-validated transmission pairs suggests that IBV experiences a tight transmission bottleneck similar to that of influenza A virus. These patterns of local-scale evolution are consistent with influenza B virus' slower global evolutionary rate.

Importance

The evolution of influenza virus is a significant public health problem and necessitates the annual evaluation of influenza vaccine formulation to keep pace with viral escape from herd immunity. Influenza B virus is a serious health concern for children, in particular, yet remains understudied compared to influenza A virus. Influenza B virus evolves more slowly than influenza A, but the factors underlying this are not completely understood. We studied how the

within-host diversity of influenza B virus relates to its global evolution by sequencing viruses from a community-based cohort. We found that influenza B virus populations have lower within-host genetic diversity than influenza A virus and experience a tight genetic bottleneck during transmission. Our work provides insights into the varying dynamics of influenza viruses in human infection.

Introduction

Influenza viruses rapidly mutate and evolve through selection, genetic drift, and reassortment (1). At a global scale, influenza A virus (IAV) and influenza B virus (IBV) evolve under strong positive selection driven by pressure for escape from pre-existing population immunity (2,3).

Selection of new antigenic variants contributes to reduced effectiveness of seasonal influenza vaccines, necessitating annual updates of vaccine strains (4). IAV and IBV both undergo seasonal antigenic drift and share a similar genomic architecture, but their ecology and evolution differ in important ways (5). While IBV accounts for roughly one-third of influenza's burden of morbidity and mortality (6,7), it circulates only in humans and is considered to be a lower pandemic risk than influenza A (IAV) due to the lack of an animal reservoir. Like IAV, there are co-circulating, antigenically-distinct lineages of IBV that are included in the quadrivalent influenza vaccine. Two lineages of IBV diverged in the 1980s, B/Victoria/2/87-like and B/Yamagata/16/88-like, here referred to as B/Victoria and B/Yamagata, respectively (8).

IBV evolves more slowly than IAV on a global scale and has a lower rate of antigenic drift, but the reasons for this are poorly understood (5,9). Similar evolutionary forces are involved in the antigenic evolution of both IAV and IBV, generally characterized by non-synonymous substitutions at antigenic sites in the surface hemagglutinin (HA) protein (10,11) and reassortment within and between lineages (12–14). The IBV polymerase has a lower mutation

rate relative to IAV (15). However, it is unclear whether the slower global evolution of IBV is driven by its lower mutation rate or other differences in selection at the global scale.

All new seasonal influenza variants are ultimately derived from *de novo* mutations within individual hosts (16). Therefore, understanding how new variants arise within individuals and transmit between them is essential to defining how novel viruses spread in host populations. For example, if the relative mutation rate is a major factor underlying the global evolutionary differences across IAV and IBV, we might also expect to see differences in their within-host dynamics. We and others have used next-generation sequencing to investigate the within- and between-host evolutionary dynamics of IAV in humans (16–21). We have found that there is little accumulation of intrahost variants during acute infections of immunocompetent individuals (18,19), and we have not found evidence of changes in intrahost diversity by vaccination status or other proxies for immunological history (19,20,22). The IAV transmission bottleneck is stringent (19), which generally means that few variants that arise within hosts are able to transmit. Together, these studies suggest that selection of novel variants is an inefficient process in IAV-infected hosts, contrasting with its patterns of significant positive selection at the global level. Despite the importance of intrahost processes to influenza virus evolution, these dynamics have not been systematically investigated in IBV.

Here we use next-generation sequencing to define the within-host diversity of IBV populations from individuals enrolled in the Household Influenza Vaccine Evaluation (HIVE) study, a community-based household cohort initiated in 2010. We apply a previously-validated bioinformatic pipeline (23) to identify intrahost single-nucleotide variants (iSNV) arising during infection with B/Victoria and B/Yamagata viruses. We find that IBV has significantly lower intrahost diversity than IAV, consistent with its lower mutation rate and slower rate of evolution. We analyze shared iSNV across 15 genetically-validated household transmission pairs and find

that, like IAV, IBV is also subject to a tight genetic bottleneck at transmission. These data provide the first systematic evaluation of the genetic architecture of IBV populations during natural human infection and provide insights into the comparative epidemiology and evolution of influenza viruses.

Results

We used high depth-of-coverage sequencing to define the intrahost genetic diversity in IBV-positive samples collected from individuals in the HIVE, a prospective, household cohort in southeastern Michigan that follows 200-350 households annually (Table 1). This cohort provides an opportunity to investigate natural infections and transmission events in a community context. Individuals that meet symptom-based criteria for an upper respiratory illness during the surveillance period undergo collection of nasal and throat swabs for molecular detection of respiratory viruses by RT-PCR. Starting in 2014-2015, individuals also provided a sample collected at home prior to subsequent collection of a second specimen at the on-site clinic.

Over seven seasons (2010-2011 through 2016-2017) and 8176 person-seasons of observation, we identified 111 individuals infected with B/Yamagata and 67 infected with B/Victoria (Table 1). Several households had clusters of infections of two or three IBV-positive individuals within 7 days of each other, suggestive of within-household transmission. Because variant identification is sensitive to input viral titer (23), we first measured viral loads of all available IBV-positive samples by RT-qPCR (Figure 1A). Any samples with a viral load below 10^3 copies/ μ L were not submitted for sequencing. For samples with a viral load in the range of 10^3 - 10^5 copies/ μ L, we performed two independent RT-PCR reactions and sequenced replicate libraries on separate sequencing runs. We sequenced samples with viral loads above 10^5 copies/ μ L of transport

media in a single replicate. From the available IBV-positive samples, we were able to obtain sequence data on 106 samples from 91 individuals, consisting of 35 individuals infected with B/Victoria and 56 infected with B/Yamagata (Table 1).

We identified intrahost single nucleotide variants (iSNV) using our previously-validated bioinformatic pipeline. As in our previous work, we report iSNV at frequencies of 2% or above, for which we have well-defined sensitivity and specificity (19). We consider sites with >98% frequency to be essentially fixed, setting the frequency at those sites to 100% (see Materials and Methods). We achieved a mean coverage of 10,000x per sample across most genome segments, with generally lower coverage on segments encoding NP and NS (Figure 1B). We restricted our analysis of iSNV to samples with an average genome coverage of greater than 1000x, which includes 99 of the original 106 sequenced samples.

Within-host genetic diversity of IBV in natural infections

All samples exhibited low genetic diversity. The vast majority had no iSNV above the 2% cutoff. Of the 99 samples with high-quality NGS data, 70 had no minority iSNV, 17 had one iSNV, 7 had two iSNV, and 3 samples had 3 iSNV (median 0, IQR 0-2; Table 2). Two outliers had a large number of iSNV, with 8 and 20 iSNV. These two samples came from the same individual, with one collected at home and the second at the study clinic. Most of the iSNV in these two samples were present at similar frequencies, 3-5% and 17-23% in each specimen, respectively (Table 3), both of which were sequenced in duplicate on separate Illumina runs. The high number of mutations present at similar frequencies is suggestive of a mixed infection with distinct haplotypes or strains as opposed to *de novo* mutations arising on a single genetic background. The iSNV in the home-collected sample are all found in the subsequent clinic-collected sample, each with a similar change in frequency across the two samples. This further

supports the conclusion that these mutations are on the same genome in a mixed infection with two distinct strains.

We examined how within-host diversity changes by day of sampling during IBV infections, as the virus population rapidly expands and contracts. As we have previously shown that specimen viral load can affect the sensitivity and specificity of variant identification (23), we sought to control for this variable in our analysis. Although viral load generally decreased with time after symptom onset (Figure 1A), we found that within-host diversity as measured by number of identified minority iSNV did not vary with viral load (Figure 2A) or with day of infection (Figure 2B). The frequencies of the identified iSNV were consistent across replicate libraries from the same samples, indicating that our measurements of iSNV frequency are precise (Figure 2C).

We detected minority iSNV across all eight genome segments (Figure 3). We identified more synonymous than nonsynonymous mutations, which given the ratio of synonymous and nonsynonymous sites indicates that purifying selection dominates within hosts. There was only one minority iSNV present in more than one individual; we identified a variant encoding a synonymous mutation in PB1 in two individuals from separate households infected with B/Yamagata in the 2016-2017 season. We did not identify any nonsynonymous minority iSNV in the known antigenic sites of IBV hemagglutinin, which suggests that positive selective pressure for variants that escape antibody-mediated immunity is not particularly strong within hosts. We found that there is no difference in the distribution of the number of iSNV per sample between vaccinated and non-vaccinated individuals (Figure 4A). During the first few seasons of the study, some individuals received trivalent vaccines, which contain only one of the two IBV lineages. We therefore repeated this analysis, excluding 3 individuals for whom we had no information about specific vaccine product and re-classifying 6 individuals who received trivalent vaccines and were infected with a lineage not included in that season's trivalent formulation as

“unvaccinated.” We again found no difference in the number of iSNV between groups (MWU test, $p = 0.9103$). Together, these data indicate that vaccine-induced immunity is not a major diversifying force for IBV within hosts in our study population. This is consistent with our previous work on IAV in the HIVE as well as a randomized-controlled trial of vaccine efficacy (FLU-VACS), both of which showed no difference in intrahost diversity based on same-season vaccination status (19,20). Intrahost diversity was similar between B/Victoria and B/Yamagata virus populations (Figure 4B), consistent with our previous comparison of subtype A/H3N2 and A/H1N1 viruses (19).

We compared the within-host genetic diversity of IBV to our previously published data on IAV from the HIVE cohort (19). Here, IBV exhibits lower within-host diversity compared to IAV (Figure 4C). To ensure our results were not an artifact of overly stringent quality thresholds, we also identified minority iSNV with less conservative read mapping quality (MapQ) and base quality (Phred) scores. We identified the same set of minority iSNV with a MapQ cut-off of 20 as with the original cutoff of 30. Similarly, reduction of the Phred base-quality cutoff to >25 in addition to a MapQ score cutoff of >20 resulted in only 20 more minority iSNV, eight of which were found in the individual with a mixed infection. The other additional 12 minority iSNV were dispersed across specimens and did not significantly change the overall distribution of within-host diversity. We also examined whether our results were biased by use of a single B/Yamagata and B/Victoria reference for alignment and variant calling, which were both drawn from the 2012-2013 season (see Materials and Methods). We realigned sequence data from 43 of the original 99 samples to season-specific reference genomes isolated in southeastern Michigan. We found that the overall alignment rate for any given specimen was similar between the original reference and the new season-matched reference. Variant identification based on the new references and the original quality thresholds resulted in the same distribution of within-host diversity, although the identity of some iSNV was different (Figure 4D).

208

209 Together, these results indicate that our measurements of within-host diversity are robust to
210 several technical aspects of variant identification and are unlikely to account for the lower
211 observed diversity of IBV. Because these data are from the same cohort and were generated
212 using the same sequencing approach and analytic pipeline as our previous IAV datasets, the
213 observed differences likely reflect true biological differences between IAV and IBV.

214

215 *Identification of household transmission pairs*

216

217 We compared viral diversity across samples from individuals in the same household to
218 investigate the genetic bottleneck that influenza B viruses experience during natural
219 transmission. Over the seven influenza seasons, thirty-nine households in the HIVE cohort had
220 two or more individuals positive for the same IBV lineage within a 7-day interval (Table 1). This
221 epidemiologic linkage is suggestive of transmission events but does not rule out co-incident
222 community acquired infection (19). We identified 16 putative transmission pairs for which we
223 sequenced at least one sample from each individual. In one of these pairs, the putative recipient
224 was the individual with a mixed infection. The donor did not have evidence of a mixed infection
225 based on number of iSNV, which would imply that the recipient may have been infected twice or
226 that the second virus was lost from the donor by the time of sampling. This pair was excluded
227 from the between-host analysis, leaving 15 putative transmission pairs for which we have high-
228 quality sequencing data on both donor and recipient influenza populations.

229

230 We used our sequencing data to determine which of these epidemiologically linked household
231 pairs were actual IBV transmission pairs. We generated maximum likelihood phylogenetic trees
232 for samples from the two IBV lineages using the concatenated coding consensus sequences.
233 Phylogenetic analysis provided genetic evidence that the 15 epidemiologically-linked pairs were

indeed true transmission pairs, as epidemiologically-linked pairs were found nearest each other in each tree (Figure 5A and 5B; vertical bars with household ID). We also validated these transmission pairs by analyzing the genetic distance across viral populations. True transmission pairs should have genetically similar populations exhibiting low genetic distance, while individuals with coincident community acquisition are more likely to have populations with a higher genetic distance. We compared the genetic distance between epidemiologically-linked household pairs and random community pairs from the same season and infected with the same IBV lineage, using L1-norm as measurement of genetic distance (Figure 5C). The distribution of random community pairs functions as a null model of genetic distances among locally circulating strains. All of the 15 putative transmission pairs fell on the tail of this distribution, below the 5th percentile of the community pair L1-norm distribution, indicating that they are true transmission pairs (Figure 5C). While the L1-norm is a function of both the consensus sequence and the iSNV, this signal was predominantly driven by consensus differences, as reflected in the phylogenetic analysis.

Comparison of viral diversity across transmission pairs

Transmission bottlenecks restrict the genetic diversity that is passed between hosts. With a loose transmission bottleneck, many unique genomes will be passed from donor to recipient. Because this will allow two variants at a given site to be transmitted, sites that are polymorphic in the donor are more likely to be polymorphic in the recipient. However, in the case of a tight or stringent bottleneck, sites that are polymorphic in the donor will likely be either fixed or absent in the recipient. We have previously demonstrated that influenza A experiences a tight transmission bottleneck of 1-2 unique genomes (19). Across our 15 IBV transmission pairs, we found no sites that were polymorphic in the donor and recipient (Figure 6). Intrahost SNV present in the donor were either fixed (100%) or absent (0%) in the recipient. These data

suggest a stringent transmission bottleneck for influenza B, similar to that of influenza A. As there were fewer samples, transmission pairs, and iSNV in our IBV dataset, we were unable to obtain a robust and precise estimate of bottleneck size.

Discussion

Here we define the within-host genetic diversity of IBV in natural infections by sequencing 106 samples collected over 8176 person-seasons of observation in a household cohort. Because the HIVE study prospectively identifies individuals with acute respiratory illness regardless of severity, these samples capture IBV dynamics in a natural setting, reflective of infections occurring in the community. We show that within-host diversity of IBV is remarkably low, with most samples displaying no intrahost variants above our level of detection. We also find that IBV experiences a tight transmission bottleneck, limiting the diversity that is passed between hosts. IBV exhibits significantly lower within-host diversity compared to IAV. These findings reflect the slower relative evolutionary rate of IBV compared to IAV.

Our findings are largely consistent with what has been observed in IAV infections in humans (17–20). We found that only a minority of samples contain iSNV, the majority of which encode synonymous changes, consistent with a predominance of purifying selection within hosts. If immune-driven selective pressures were sufficiently strong to drive positive selection of antigenic variants at the individual level, we would expect to see enrichment of variants in antigenic regions. However, variants were no more common in the antigenic proteins, hemagglutinin and neuraminidase, and we found no intrahost variants in known antigenic regions of hemagglutinin. We also found that the extent of within-host diversity did not vary with current-season vaccination status, further suggesting that immune selection is not particularly strong within hosts (19,20,22). Our data suggest that selective sweeps occur infrequently at the

individual level, with selection only evident over a broader scale of time and space (19,35). We recognize, however, that it is possible for individual level selective pressure to vary in magnitude by age, locale, influenza infection history, or immune status (36).

We do find that there are important differences in the within-host evolution of IAV and IBV. IBV displays significantly lower within-host diversity compared to IAV. Since measurements of within-host diversity can vary based on host population, sequencing approach, and variant calling algorithm (37), a strength of our study is that our comparison is based on samples from the same cohort with the same sequencing approach and analytic pipeline. In both of our studies, we have sequenced swab samples directly without prior culture, accounted for the confounding effect of viral load, and used a standardized, empirically-validated analytic pipeline for variant identification (23). This pipeline includes rigorous quality criteria to reduce false positives that can be introduced by amplification and Illumina sequencing. Importantly, these empirical quality criteria did not mask diversity actually present in these samples, strengthening the conclusion that IBV exhibits lower within-host diversity compared to IAV.

The most likely biological explanation for IBV's lower within-host diversity is its *de novo* mutation rate, which is thought to be at least two-fold lower than that of IAV (15). Viral mutation rates are critical to the diversification of rapidly evolving viruses within hosts. Under a neutral model, the number and frequency of minority variants is dependent on the mutation rate and demographics of the population (16). In such a model, the expected number of variants is highly sensitive to variation in the mutation rate across the range commonly estimated in RNA viruses. In light of our results, a more thorough comparison of mutation rates across influenza viruses is needed.

Another possible factor underlying IBV's reduced diversity is the mutational robustness of the IBV genome relative to IAV. If IBV were less robust to mutation, stronger negative selection on

multiple genes in IBV could result in more limited within-host diversity, perhaps located to certain regions of the genome. However, we found that the distributions of iSNV across IAV and IBV genomes are relatively similar. Furthermore, we have previously shown that the distribution of mutational fitness effects in influenza A/WSN/33/H1N1 matches that of other RNA and ssDNA viruses (38). Given that viruses across families with vastly different genomic architecture have similar mutational robustness, this is unlikely to account for the differences in within-host diversity between IAV and IBV.

We find that IBV experiences a stringent genetic bottleneck between hosts. A stringent transmission bottleneck places a constraint on the rate of adaptation of viral populations within and between individual hosts. Population bottlenecks reduce the effective population size, which increases random genetic drift and decreases the efficiency of selection (39). This results in a reduced ability of selection to fix beneficial mutations and to remove deleterious ones, which can decrease population fitness. However, there are potential evolutionary advantages to stringent bottlenecks, including removal of defective interfering particles (40,41). While we were not able to estimate the size of the transmission bottleneck as precisely as IAV, it is likely that the bottleneck size is comparable across the two viruses given the similarities in their transmission routes and ecology in the human population. Data from many more transmission pairs will be necessary for a more robust estimate.

Together, our results are consistent with the slower rate of global evolution observed in IBV lineages compared with both seasonal A/H1N1 and A/H3N2 (10,12,14,42). We suggest that a lower intrinsic mutation rate leads to reduced within-host diversity. With a comparably tight bottleneck, fewer *de novo* variants will rise to a level where they can be transmitted and spread through host populations. Combined with a lower incidence of IBV versus IAV, this would result in fewer variants that eventually spread and influence global dynamics. However, further

investigation in larger populations will be required to evaluate the within-host dynamics of both types of seasonal influenza viruses and how they contribute to larger-scale evolutionary patterns.

Materials and Methods

Description of the HIVE cohort

The HIVE study is a prospective, community-based household cohort in Southeastern Michigan based at the University of Michigan School of Public Health (24–29). The cohort was initiated in 2010, with enrollment of households with children occurring on an annual basis and an active surveillance period lasting from October through May. In 2014, active surveillance was expanded to take place year-round. Participating adults provided informed consent for themselves and their children, and children ages 7-17 provided oral assent. Individuals in each household were followed prospectively for acute respiratory illness, defined as two or more of the following: cough, fever or feverishness, nasal congestion, chills, headache, body aches, or sore throat. Study participants meeting the criteria for acute respiratory illness attended a study research clinic at the University of Michigan School of Public Health where a combined throat and nasal swab, or a nasal swab only for children less than three years old, was collected by the study team. Beginning in the 2014-2015 season, study participants with acute respiratory illnesses took an additional nasal swab at home at the time of illness onset, collected either by themselves or by a parent. The study was approved by the Institutional Review Board of the University of Michigan Medical School.

Viral detection, lineage typing, and viral load quantification

We processed upper respiratory specimens (combined nasal and throat swab or nasal swab) for confirmation of influenza virus infection by reverse transcription polymerase chain reaction (RT-PCR). We extracted viral RNA with either QIAamp Viral RNA Mini Kits (Qiagen) or PureLink Pro 96 Viral RNA/DNA Purification kits (Invitrogen) and tested samples using the SuperScript III Platinum One-Step Quantitative RT-PCR System with ROX (Invitrogen) and primers and probes for universal detection of influenza A and B (CDC protocol, 28 April 2009). Specimens positive for influenza virus were tested using subtype/lineage primer and probe sets, which are designed to detect influenza A (H3N2), A (H1N1)pdm09, B (Yamagata), and B (Victoria). An RNaseP primer/probe set was run for each specimen to confirm specimen quality and successful RNA extraction.

We quantified the viral load in each sample by RT-qPCR using primers specific for the open reading frame of segment 8 (NS1/NEP): forward primer 5'-TCCTCAACTCACTCTTCGAGCG-3', reverse primer 5'-CGGTGCTCTTGACCAAATTGG-3', and probe 5'-(FAM)-CCAATTCGAGCAGCTGAACTGCGGTG-(BHQ1)-3'. Each reaction contained 5.4 µL of nuclease-free water, 0.5 µL of each primer at 50 µM, 0.1 µL of ROX dye, 0.5 µL SuperScript III RT/Platinum Taq enzyme mix, 0.5 µL of 10 µM probe, 12.5 µL of 2x PCR buffer master mix, and 5 µL of extracted viral RNA. To relate genome copy number to Ct value, we used a standard curve based on serial dilutions of a plasmid control, run in duplicate on the same plate.

Amplification, library preparation, and sequencing

We amplified viral cDNA from all eight genomic segments using the SuperScript III One-Step RT-PCR Platinum Taq HiFi Kit (Invitrogen). Each reaction contained 5 µL of extracted viral RNA, 12.5 µL of 2x PCR buffer, 2 µL of primer cocktail, 0.5 µL of enzyme mix, 5 µL of nuclease-

free water. The primer cocktail was a mixture of B-PBs-UniF, B-PBs-UniR, B-PA-UniF, B-PA-UniR, B-HANA-UniF, B-HANA-UniR, B-NP-UniF, B-NP-UniR, B-M-Uni3F, B-Mg-Uni3F, B-M-Uni3R, B-NS-Uni3F, and B-NS-Uni3R (sequences and proportions are listed in ref. (30)). The thermocycler protocol was: 45 °C for 60 min, 55 °C for 30 min, 94 °C for 2 min, then 5 cycles of 94 °C for 20 s, 40 °C for 30 s, 68 °C for 3 min 30 s, then 40 cycles of 94 °C for 20 s, 58 °C for 30 s, 68 °C for 3 min 30 s, and a final extension of 68 °C for 10 min. We confirmed IBV genome amplification by gel electrophoresis. We sheared amplified cDNA (100-500 ng) on a Covaris ultrasonicator with the following settings: time 80 sec, duty cycle 10%, intensity 4, cycles per burst 200. We prepared sequencing libraries with NEBNext Ultra DNA Library Prep kits (NEB) and sequenced them on an Illumina NextSeq with 2x150 paired end reads (mid-output run, v2 chemistry). To increase the specificity of variant identification, samples with a viral load between 10^3 and 10^5 genome copies/ μ L of transport media were amplified and sequenced in duplicate. Samples amplified from B/Victoria and B/Yamagata plasmid clones were included on each sequencing run to account for sequencing errors. The plasmids used in the control reactions were generated by segment-specific RT-PCR from clinical samples of B/Victoria and B/Yamagata strains from the 2012-2013 season followed by gel extraction and TOPO-TA cloning (Invitrogen). The sequence of each plasmid was determined by Sanger sequencing. We generated the plasmid control amplicons included on each Illumina sequencing run using the same multiplex amplification protocol, but with cloned plasmid DNA as the template.

Identification of iSNV

Intrahost single-nucleotide variants (iSNV) were identified using a previously-described analytic pipeline (23). We identified iSNV in samples that had an average genome coverage greater than 1000x and a viral load greater than 10^3 genome copies per microliter of transport media in the original sample. Sequencing adapters were removed with cutadapt (31) and reads were

aligned to the sequences derived from the B/Victoria and B/Yamagata plasmid controls with Bowtie2 (32). Duplicate reads were marked and removed with Picard and samtools (33). Putative variants were identified with the R package deepSNV using data from the clonal plasmid controls of each sequencing run (34). Minority iSNV (<50% frequency) were identified using the following empirically-derived criteria: deepSNV p-value <0.01, average mapping quality >30, average Phred score >35, and average read position in the middle 50% (positions 37 and 113 for 150 base pair reads). For samples processed in duplicate, we used only variants that were present in both replicates; the frequency of the variant in the replicate with greater coverage at that site was used. Lastly, variants with frequency <2%, which have a higher false positive rate from RT-PCR and/or sequencing errors, were not included in downstream analyses.

In our previous work on IAV, we found that there were multiple sites with mutations that were essentially fixed (>0.95) relative to the plasmid control and in which the base in the plasmid control was therefore identified as a minority variant in the sample (19). At these sites, deepSNV is unable to estimate the base-specific error rate and cannot distinguish true minority iSNV; however, we found that we could accurately identify minority variants at these sites at a frequency of 2% or above (19). This frequency threshold was incorporated into the pipeline for iSNV identification at these sites. Therefore, we report intrahost variants from 2-98%; minority iSNV are the subset of these variants with a frequency between 2-50%. Any sites that were monomorphic after applying quality filters were assigned a frequency of 100%.

Data and code availability

Raw sequence data, with human content filtered out, are available at the NCBI Sequence Read Archive under BioProject accession number PRJNA561158. Code for the variant identification

pipeline is available at http://github.com/lauringlab/variant_pipeline. Analysis code is available at http://github.com/lauringlab/Host_level_IBV_evolution.

Acknowledgements

We acknowledge the individuals enrolled in the HIVE study for their participation. We thank Maria Virgilio for technical assistance. This work was supported by NIH R01 AI 118886, NIH R21 AI 141832 and a Burroughs Wellcome Fund Investigator in the Pathogenesis of Infectious Diseases award to ASL. The HIVE cohort was supported by CDC U01 IP 001034 to ASM and ETM, and CDC U01 IP000474 and NIH R01 097150 to ASM. ALV was supported by NIH T32 GM 007863.

References

1. Moya A, Holmes EC, González-Candelas F. The population genetics and evolutionary epidemiology of RNA viruses. *Nat Rev Microbiol.* 2004 Apr;2(4):279–88.
2. Rambaut A, Pybus OG, Nelson MI, Viboud C, Taubenberger JK, Holmes EC. The genomic and epidemiological dynamics of human influenza A virus. *Nature.* 2008 May;453(7195):615–9.
3. Nelson MI, Holmes EC. The evolution of epidemic influenza. *Nat Rev Genet.* 2007 Mar;8(3):196–205.
4. Yamayoshi S, Kawaoka Y. Current and future influenza vaccines. *Nat Med.* 2019 Jan 28;1.
5. Petrova VN, Russell CA. The evolution of seasonal influenza viruses. *Nat Rev Microbiol.* 2018 Jan;16(1):47–60.
6. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States. *JAMA.* 2003 Jan 8;289(2):179–86.
7. Paul Glezen W, Schmier JK, Kuehn CM, Ryan KJ, Oxford J. The Burden of Influenza B: A Structured Literature Review. *Am J Public Health.* 2013 Jan 17;103(3):e43–51.
8. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. *Virology.* 1990 Mar 1;175(1):59–68.
9. Yamashita M, Krystal M, Fitch WM, Palese P. Influenza B virus evolution: Co-circulating lineages and comparison of evolutionary pattern with those of influenza A and C viruses. *Virology.* 1988 Mar 1;163(1):112–22.
10. Chen R, Holmes EC. The Evolutionary Dynamics of Human Influenza B Virus. *J Mol Evol.* 2008 May 27;66(6):655.
11. Shen J, Kirk BD, Ma J, Wang Q. Diversifying selective pressure on influenza B virus hemagglutinin. *J Med Virol.* 2009;81(1):114–24.
12. Langat P, Raghwanji J, Dudas G, Bowden TA, Edwards S, Gall A, et al. Genome-wide evolutionary dynamics of influenza B viruses on a global scale. *PLOS Pathog.* 2017 Dec 28;13(12):e1006749.
13. Dudas G, Bedford T, Lycett S, Rambaut A. Reassortment between Influenza B Lineages and the Emergence of a Coadapted PB1–PB2–HA Gene Complex. *Mol Biol Evol.* 2015 Jan 1;32(1):162–72.
14. Vijaykrishna D, Holmes EC, Joseph U, Fourment M, Su YC, Halpin R, et al. The contrasting phylodynamics of human influenza B viruses. Neher RA, editor. *eLife.* 2015 Jan 16;4:e05055.

- 488 15. Nobusawa E, Sato K. Comparison of the Mutation Rates of Human Influenza A and B
489 Viruses. *J Virol.* 2006 Apr 1;80(7):3675–8.
- 490 16. Xue KS, Moncla LH, Bedford T, Bloom JD. Within-Host Evolution of Human Influenza
491 Virus. *Trends Microbiol.* 2018 Sep 1;26(9):781–93.
- 492 17. Dinis JM, Florek NW, Fatola OO, Moncla LH, Mutschler JP, Charlier OK, et al. Deep
493 Sequencing Reveals Potential Antigenic Variants at Low Frequencies in Influenza A Virus-
494 Infected Humans. *J Virol.* 2016 Apr 1;90(7):3355–65.
- 495 18. Leonard AS, McClain MT, Smith GJD, Wentworth DE, Halpin RA, Lin X, et al. Deep
496 Sequencing of Influenza A Virus from a Human Challenge Study Reveals a Selective
497 Bottleneck and Only Limited Intrahost Genetic Diversification. *J Virol.* 2016 Dec
498 15;90(24):11247–58.
- 499 19. McCrone JT, Woods RJ, Martin ET, Malosh RE, Monto AS, Luring AS. Stochastic
500 processes constrain the within and between host evolution of influenza virus. Neher RA,
501 editor. *eLife.* 2018 Apr 23;7:e35962.
- 502 20. Debbink K, McCrone JT, Petrie JG, Truscon R, Johnson E, Mantlo EK, et al. Vaccination
503 has minimal impact on the intrahost diversity of H3N2 influenza viruses. *PLOS Pathog.*
504 2017 Jan 31;13(1):e1006194.
- 505 21. Xue KS, Bloom JD. Reconciling disparate estimates of viral genetic diversity during human
506 influenza infections. *Nat Genet.* 2019 Feb 25;1.
- 507 22. Han AX, Maurer-Stroh S, Russell CA. Individual immune selection pressure has limited
508 impact on seasonal influenza virus evolution. *Nat Ecol Evol.* 2018 Dec 3;1.
- 509 23. McCrone JT, Luring AS. Measurements of Intrahost Viral Diversity Are Extremely
510 Sensitive to Systematic Errors in Variant Calling. *J Virol.* 2016 Aug 1;90(15):6884–95.
- 511 24. Petrie JG, Malosh RE, Cheng CK, Ohmit SE, Martin ET, Johnson E, et al. The Household
512 Influenza Vaccine Effectiveness Study: Lack of Antibody Response and Protection
513 Following Receipt of 2014–2015 Influenza Vaccine. *Clin Infect Dis.* 2017 Oct
514 30;65(10):1644–51.
- 515 25. Monto AS, Malosh RE, Petrie JG, Thompson MG, Ohmit SE. Frequency of Acute
516 Respiratory Illnesses and Circulation of Respiratory Viruses in Households With Children
517 Over 3 Surveillance Seasons. *J Infect Dis.* 2014 Dec 1;210(11):1792–9.
- 518 26. Ohmit SE, Petrie JG, Malosh RE, Johnson E, Truscon R, Aaron B, et al. Substantial
519 Influenza Vaccine Effectiveness in Households With Children During the 2013–2014
520 Influenza Season, When 2009 Pandemic Influenza A(H1N1) Virus Predominated. *J Infect*
521 *Dis.* 2016 Apr 15;213(8):1229–36.
- 522 27. Ohmit SE, Petrie JG, Malosh RE, Cowling BJ, Thompson MG, Shay DK, et al. Influenza
523 Vaccine Effectiveness in the Community and the Household. *Clin Infect Dis.* 2013 May
524 15;56(10):1363–9.

- 525 28. Petrie JG, Ohmit SE, Cowling BJ, Johnson E, Cross RT, Malosh RE, et al. Influenza
526 Transmission in a Cohort of Households with Children: 2010-2011. PLOS ONE. 2013 Sep
527 25;8(9):e75339.
- 528 29. Monto AS, Malosh RE, Evans R, Luring AS, Gordon A, Thompson MG, et al. Data
529 resource profile: Household Influenza Vaccine Evaluation (HIVE) Study. Int J Epidemiol.
530 2019 Aug 1;48(4):1040–1040g.
- 531 30. Zhou B, Lin X, Wang W, Halpin RA, Bera J, Stockwell TB, et al. Universal Influenza B
532 Virus Genomic Amplification Facilitates Sequencing, Diagnostics, and Reverse Genetics. J
533 Clin Microbiol. 2014 May 1;52(5):1330–7.
- 534 31. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads.
535 EMBnet.journal. 2011 May 2;17(1):10–2.
- 536 32. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012
537 Apr;9(4):357–9.
- 538 33. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence
539 Alignment/Map format and SAMtools. Bioinformatics. 2009 Aug 15;25(16):2078–9.
- 540 34. Gerstung M, Beisel C, Rechsteiner M, Wild P, Schraml P, Moch H, et al. Reliable detection
541 of subclonal single-nucleotide variants in tumour cell populations. Nat Commun. 2012 May
542 1;3:811.
- 543 35. Nelson MI, Simonsen L, Viboud C, Miller MA, Taylor J, George KS, et al. Stochastic
544 Processes Are Key Determinants of Short-Term Evolution in Influenza A Virus. PLOS
545 Pathog. 2006 Dec 1;2(12):e125.
- 546 36. Lee JM, Eguia R, Zost SJ, Choudhary S, Wilson PC, Bedford T, et al. Mapping person-to-
547 person variation in viral mutations that escape polyclonal serum targeting influenza
548 hemagglutinin. Lipsitch M, Kirkegaard K, Lipsitch M, editors. eLife. 2019 Aug 27;8:e49324.
- 549 37. Grubaugh ND, Gangavarapu K, Quick J, Matteson NL, De Jesus JG, Main BJ, et al. An
550 amplicon-based sequencing framework for accurately measuring intrahost virus diversity
551 using PrimalSeq and iVar. Genome Biol. 2019 Jan 8;20(1):8.
- 552 38. Visher E, Whitefield SE, McCrone JT, Fitzsimmons W, Luring AS. The Mutational
553 Robustness of Influenza A Virus. PLOS Pathog. 2016 Aug 29;12(8):e1005856.
- 554 39. McCrone JT, Luring AS. Genetic bottlenecks in intraspecies virus transmission. Curr Opin
555 Virol. 2018 Feb 1;28:20–5.
- 556 40. Zwart MP, Elena SF. Matters of Size: Genetic Bottlenecks in Virus Infection and Their
557 Potential Impact on Evolution. Annu Rev Virol. 2015 Nov 6;2(1):161–79.
- 558 41. Vignuzzi M, López CB. Defective viral genomes are key drivers of the virus–host
559 interaction. Nat Microbiol. 2019 Jun 3;1.
- 560 42. Bedford T, Riley S, Barr IG, Broor S, Chadha M, Cox NJ, et al. Global circulation patterns
561 of seasonal influenza viruses vary with antigenic drift. Nature. 2015 Jul;523(7559):217–20.

Figure Legends

Figure 1. Viral load and sequencing coverage. (A) Boxplot of viral load (genome copies per microliter of swab transport media, y-axis) by day of sampling relative to symptom onset (x-axis). The boxes display median and 25th and 75th percentiles, with whiskers extending to the most extreme point within the range of the median $\pm$ 1.5 times the interquartile range; all values outside this range are shown as individual points. (B) Sequencing coverage is plotted with read depth on the y-axis and location within a concatenated influenza B virus genome on the x-axis. The mean coverage for each sample was calculated over a sliding window of size 200 and a step size of 100. The data are displayed for all samples at each window as a boxplot, showing the median and 25th and 75th percentiles, with whiskers extending to the most extreme point within the range of the median $\pm$ 1.5 times the interquartile range; all values outside this range are shown as individual points.

Figure 2. Intrahost minority SNV by day post-symptom onset and viral load. (A) Number of minority iSNV per sample is plotted on the y-axis by day post symptom onset on the x-axis. Data are displayed as boxplots representing the median and 25th and 75th percentiles, with whiskers extending to the most extreme point within the range of the median $\pm$ 1.5 times the interquartile range. The raw data points are overlaid on top of the boxplots. (B) Scatterplot relating the number of minority iSNV per sample on the y-axis to the log₁₀ of viral load, in genome copies per microliter, on the x-axis. (C) Frequency of minority iSNV in samples sequenced in duplicate. Orange dots represent variants identified in samples with viral load of 10³ – 10⁴ genome copies per microliter and blue dots represent variants in samples with viral load of 10⁴ – 10⁵ genome copies per microliter.

Figure 3. Intrahost SNV frequency by genome position and mutation type. All minority (<50%) iSNV from 99 samples are displayed with their frequency on the y-axis and their position within a concatenated influenza B virus genome on the x-axis. Synonymous mutations are shown in orange and nonsynonymous mutations in blue.

Figure 4. Intrahost SNV by vaccination status and IBV lineage. (A) Numbers of minority iSNV per sample across all 99 samples are shown (y-axis) by current-season vaccination status of the host (x-axis). (B) Numbers of minority iSNV per sample are shown (y-axis) by IBV lineage (x-axis). (C) Numbers of minority iSNV per sample are shown (y-axis) by influenza virus type (x-axis). Data for influenza A virus are from 249 samples described in McCrone et al. 2018. Data on influenza B virus are from 99 high-quality samples in the present study. (D) Numbers of minority iSNV in 43 of the 99 high-quality samples (y-axis), consisting of B/Yamagata from the 2014/2015 season, B/Victoria from the 2015/2016 season, and B/Yamagata from the 2016/2017 season based on alignments to the original references from the 2012/2013 season vs. season-matched reference genomes (x-axis).

Figure 5. Identification of household transmission pairs. Maximum likelihood phylogenetic tree of all B/Victoria (A) and B/Yamagata (B) samples from this study. Concatenated consensus coding sequences were aligned with MUSCLE and phylogenetic trees constructed with RAxML. Tip labels are denoted as enrollee ID, household ID, season, and lineage, separated by underscores; tip labels are color-coded by household ID. (C) Histogram of genetic distance, as measured by L1-norm, between household pairs and random community pairs from the same season and lineage. The bar heights for each group are normalized to the maximum for each group for comparison. Community pairs are shown in orange and household pairs shown in blue. The dotted red line indicates the 5th percentile of the community pair distribution.

613 **Figure 6.** Shared diversity across household transmission pairs with influenza B virus. Intrahost
 614 SNV for 15 validated transmission pairs using samples closest to the time of transmission
 615 (inferred based on day of symptom onset). Each iSNV is plotted as a point with its frequency in
 616 the recipient (y-axis) versus its frequency in the donor (x-axis).

Table 1. Influenza B viruses over seven seasons in a household cohort

	2010- 2011	2011- 2012	2012- 2013	2013- 2014	2014- 2015	2015- 2016	2016- 2017
Households	328	213	321	232	340	227	208
Participants	1441	943	1426	1049	1431	996	890
Vaccinated n(%) ^a	934 (65)	554 (59)	942 (66)	722 (69)	992 (69)	681 (68)	611 (69)
IBV Positive Individuals ^b	45	7	49	4	44	11	30
B/Yamagata	1	3	38	4	34	5	26
B/Victoria	37	0	10	0	10	6	4
IBV Positive Households ^c							
Two Individuals	10	2	5	0	11	2	4
Three Individuals	0	1	1	0	1	0	2
High Quality NGS Data ^d	13	2	20	1	32	11	20

^a Self-reported or confirmed receipt of vaccine prior to the specified season.

^b RT-PCR confirmed infection.

^c Households in which two individuals were positive within 7 days of each other. In cases of trios, the putative chains could have no pair with onset >7 days apart.

^d Samples with >10³ genome copies per µl of transport medium, adequate amplification of all 8 genomic segments, and average sequencing coverage >10³ per nucleotide.

Table 2. Identified iSNV, excluding samples from one putative mixed infection.

Enrollee	Specimen	Season	Lineage	Viral Load ^a	Gene	Nucleotide ^b	Amino Acid ^c	Frequency	Coverage ^d	Mutation Type ^e	Vaccinate ^f
50207	MH15919	16/17	B/Victoria	3.50E+03	M	A650G	N207S	0.024	13574	NS	IIV4
331001	MH2671	12/13	B/Victoria	3.20E+05	NA	C276T	L73F	0.086	6107	NS	LAIV3
331001	MH2671	12/13	B/Victoria	3.20E+05	PA	A2047G	K671R	0.474	5024	NS	LAIV3
330171	MH3227	12/13	B/Victoria	7.00E+06	NA	A385C	N109T	0.162	14964	NS	IIV3
330171	MH3227	12/13	B/Victoria	7.00E+06	PA	C1982T	A649A	0.461	8159	S	IIV3
301587	M53957	10/11	B/Victoria	3.30E+04	HA	G1603A	G522R	0.081	34517	NS	No
301587	M53957	10/11	B/Victoria	3.30E+04	NA	A863C	T268T	0.038	45106	S	No
301202	M54308	10/11	B/Victoria	4.40E+04	PA	C1037T	N334N	0.195	20857	S	No
50003	MH10403	14/15	B/Victoria	8.20E+04	NS	A103C	T18T	0.063	3245	S	No
50004	MH10404	14/15	B/Victoria	8.20E+04	NP	A577G	N171S	0.057	13413	NS	No
50004	MH10404	14/15	B/Victoria	8.20E+04	NA	A1457G	L466L	0.223	4398	S	No
50004	MH10404	14/15	B/Victoria	8.20E+04	PA	G1617A	V528M	0.497	17758	NS	No
50424	HS1876	14/15	B/Victoria	1.60E+03	NP	G1191A	D376N	0.034	1073	NS	IIV4
50051	HS1909	14/15	B/Victoria	1.90E+03	M	G709A	E227K	0.343	2138	NS	Yes, Unk
50004	HS1788	14/15	B/Victoria	8.30E+05	NP	A577G	N171S	0.054	12857	NS	No
50004	HS1788	14/15	B/Victoria	8.30E+05	PA	G1617A	V528M	0.389	16217	NS	No
50004	HS1788	14/15	B/Victoria	8.30E+05	NA	A1457G	L466L	0.045	3259	S	No
50312	HS2019	15/16	B/Victoria	2.00E+05	NP	G987A	V308I	0.420	6593	NS	No
50312	HS2019	15/16	B/Victoria	2.00E+05	PA	G1346A	E437E	0.467	9225	S	No
51123	HS2680	15/16	B/Victoria	3.50E+05	NP	G1511A	R482R	0.344	7393	S	No
320779	MH0776	11/12	B/Yamagata	3.40E+05	NP	A735G	S223S	0.023	9674	S	IIV3
320779	MH0776	11/12	B/Yamagata	3.40E+05	PB2	G661A	R211R	0.222	14675	S	IIV3
51092	MH10076	14/15	B/Yamagata	1.20E+04	PB1	A223G	I66V	0.116	7370	NS	IIV4
50650	MH16167	16/17	B/Yamagata	5.20E+04	PA	T2019C	L662L	0.373	5397	S	IIV4
50650	MH16167	16/17	B/Yamagata	5.20E+04	PB1	C345T	A106A	0.159	6639	S	IIV4
331060	MH3065	12/13	B/Yamagata	3.70E+05	PA	A1912G	K626R	0.051	10393	NS	LAIV3
331397	MH4247	12/13	B/Yamagata	2.40E+04	PB2	A676G	R216R	0.370	20110	S	IIV3
330459	MH4289	12/13	B/Yamagata	2.10E+05	HA	G1102A	A355T	0.024	14033	NS	IIV3
330460	MH4364	12/13	B/Yamagata	2.10E+05	PB2	G520A	V164V	0.032	7919	S	IIV3
50006	MH16139	16/17	B/Yamagata	1.20E+05	HA	T728C	F230S	0.148	14877	NS	No
331471	MH2216	12/13	B/Yamagata	8.60E+04	PB2	G1936A	Q636Q	0.024	30012	S	No
331470	MH2246	12/13	B/Yamagata	1.20E+04	PA	G1535A	A500A	0.029	9483	S	No
331470	MH2246	12/13	B/Yamagata	1.20E+04	PB2	A2253G	K742R	0.124	4478	NS	No
331470	MH2246	12/13	B/Yamagata	1.20E+04	PB2	C769T	H247H	0.023	12295	S	No
331364	MH4166	12/13	B/Yamagata	2.80E+04	HA	C746T	T236I	0.037	29665	NS	No
331364	MH4166	12/13	B/Yamagata	2.80E+04	PA	G1298A	L421L	0.093	15898	S	No
UM41536	MH6592	13/14	B/Yamagata	2.00E+04	PB1	G1893A	R622R	0.022	20159	S	No
51093	HS1747	14/15	B/Yamagata	3.90E+04	PA	G1433A	L466L	0.087	5646	S	IIV4
50419	HS3214	16/17	B/Yamagata	5.40E+05	PB1	C345T	A106A	0.046	7545	S	IIV4
51121	HS3258	16/17	B/Yamagata	1.10E+04	PB1	A2079G	E684E	0.022	17567	S	No

^a Viral load measured by RT-qPCR, expressed in genome copies per microliter of transport medium.

^b Consensus nucleotide followed by position on reference genome and variant nucleotide.

^c Consensus amino acid followed by codon position on reference genome and variant amino acid.

^d Coverage expressed as the total sequencing read depth at the site of the identified variant.

^e Nonsynonymous (NS) or synonymous (S) variant relative to sample consensus.

^f Self-reported or confirmed receipt of vaccine prior to the specified season. IIV4, quadrivalent inactivated; LAIV3, trivalent live attenuated; IIV3, trivalent inactivated; Unk, vaccine product unknown.

Table 3. Identified iSNV in one vaccinated individual^a with a putative mixed infection during the 2014-2015 season.

Specimen ^a	Viral Load ^b	Gene	Nucleotide ^c	Amino Acid ^d	Frequency	Coverage ^e	Mutation Type ^f
HS1875	2.90E+04	HA	G1061A	R341K	0.029	22065	NS
HS1875	2.90E+04	NP	G1666A	G534D	0.027	4688	NS
HS1875	2.90E+04	NA	G1210A	G384D	0.054	20907	NS
HS1875	2.90E+04	NA	A798G	S247G	0.052	25817	NS
HS1875	2.90E+04	NS	G1004A	V100V	0.045	1944	S
HS1875	2.90E+04	PB2	G817A	V263V	0.036	24333	S
HS1875	2.90E+04	PB2	A1231C	I401I	0.032	26905	S
HS1875	2.90E+04	PB2	A793G	E255E	0.035	23840	S
MH10536	3.80E+04	HA	G1061A	R341K	0.236	21341	NS
MH10536	3.80E+04	HA	C366T	C109C	0.213	17059	S
MH10536	3.80E+04	M	A114G	L28L	0.189	2792	S
MH10536	3.80E+04	NP	G1666A	G534D	0.193	3039	NS
MH10536	3.80E+04	NP	G1257A	R398R	0.166	11007	S
MH10536	3.80E+04	NA	G1210A	G384D	0.239	20531	NS
MH10536	3.80E+04	NA	C1286T	Y409Y	0.218	16887	S
MH10536	3.80E+04	NA	C1319T	C420C	0.217	12891	S
MH10536	3.80E+04	NA	G1148A	R363R	0.225	23087	S
MH10536	3.80E+04	NA	A798G	S247G	0.233	24631	NS
MH10536	3.80E+04	NA	T816C	F253L	0.06	24779	NS
MH10536	3.80E+04	NS	G1004A	V100V	0.185	1310	S
MH10536	3.80E+04	NS	G596A	V183I	0.190	10074	NS
MH10536	3.80E+04	NS	T469A	V140V	0.198	8807	S
MH10536	3.80E+04	NS	T66C	M6T	0.173	1986	NS
MH10536	3.80E+04	PA	G1279A	S415N	0.188	19813	NS
MH10536	3.80E+04	PB1	T1932A	S635S	0.214	19999	S
MH10536	3.80E+04	PB2	G817A	V263V	0.217	17558	S
MH10536	3.80E+04	PB2	A1231C	I401I	0.218	19869	S
MH10536	3.80E+04	PB2	A793G	E255E	0.221	17325	S

^a Enrollee number 50425. HS Indicates home specimen and MH indicates clinic specimen, both from same individual

^b Viral load measured by RT-qPCR, expressed in genome copies per microliter of transport medium.

^c Consensus nucleotide followed by position on reference genome and variant nucleotide.

^d Consensus amino acid followed by codon position on reference genome and variant amino acid.

^e Coverage expressed as the total sequencing read depth at the site of the identified variant.

^f Nonsynonymous (NS) or synonymous (S) variant relative to sample consensus.

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6